Ramos EAB, Ponce LH, Ramírez HL, Arenas R

Language: Spanish
References: 15
Page: 192-195
PDF size: 151.43 Kb.

ABSTRACT

Balanitis and vulvovaginitis caused by Candida spp. can be treated with topical or systemic azolic derivates, depending on the severity. Itraconazole inhibits fungal 14α-demethylase, leading to the reduction of ergosterol. It is known that a low pH increases antifungal absorption and a high pH decreases it. The SUBA technology improves bioavailability, achieving between patients and inpatient variability and resulting in a more predictable clinical response. We present a balanitis, and a vulvovaginitis case caused by C. albicans with an excellent response to this drug.

REFERENCES

1. Wray AA y Khetarpal S, Balanitis, StatPearls Internet Treasure Island 2019.

2. Araiza J, Montes de Oca G, Ponce RM y Bonifaz A, Balanitis y balanopostitis candidósica. Comunicación de 20 casos, Dermatología Rev Mex 2011; 55(6):342-6.

3. Murina F, Graziottin A, Felice R, Radizi GL y Di Francesco S, The recurrent vulvovaginal candidiasis: proposal of a personalized therapeutic protocol, isrn obstetrics and gynecology 2011; 2011:806065.

4. Donders GG y Sobel JD, Candida vulvovaginitis: a store with a buttery and a show window, Mycoses 2017; 60(2):70-2.

5. Pineda J, Cortés AA, Uribarren NJ y Castañón LR, Candidosis vaginal. Revisión de la literatura y situación de México y otros países latinoamericanos, Rev Méd Risaralda 2017; 23(1):38-44.

6. Goje O y Munoz JL, Vulvovaginitis: find the cause to treat it, Cleve Clin J Med 2017; 84(3):215-24.

7. Arenas R, Micología médica ilustrada, 5ª ed., Mexico, McGraw-Hill, 2014, pp. 239-260.

8. Allen D, Wilson D, Drew R y Perfect J, Azole antifungals: 35 years of invasive fungal infection management, Expert Rev Anti Infect Ther 2015; 13(6):787-98.

9. De Beule K, Van Gestel J, Pharmacology of itraconazole, Drugs 2001; 61 suppl 1:27-37.

10. Piérard GE, Arrese JE y Piérard-Franchimont C, Itraconazole, Expert Opinion on Pharmacotherapy 2000; 1(2):287-304.

11. Ministerio de Sanidad Política, Social e Igualdad, Ficha técnica Itragerm 50 mg, Agencia Española de Medicamentos y Productos Sanitarios, 2017.

12. Lindsay J, Mudge S, George R, Thompson III, Effects of food and omeprazole on novel formulation suba-itraconazole in healthy subjects, Antimicrobial Agents and Chemotherapy 2018; 62(12):e01723-28.

13. Lindsay J, Sandaradura I, Wong K, Arthur C, Stevenson W y Kerridge I, Serum levels, safety and tolerability of new formulation suba-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation, J Antimicrob Chemother 2017; 72(12):3414-19.

14. Abuhelwa AY, Foster DJ, Mudge S, Hayes D y Upton RN, Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral suba-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states, Antimicrob Agents Chemother 2015; 59(9):5681-96.

15. Abuhelwa AY, Mudge S, Upton RN y Foster DJR, Population in vitro–in vivo pharmacokinetic model of first-pass metabolism: itraconazole and hydroxy-itraconazole, J Pharmacokinet Pharmacodyn 2018; 45:181-97.